Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsGenital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, astrocytoma (excluding glioblastoma), brain cancer, brain disorder, breast cancer, breast disorder, breast neoplasm, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, male reproductive organ cancer, male reproductive system disorder, melanocytic neoplasm, melanoma, metastatic melanoma, metastatic prostate carcinoma, neoplasm, nervous system disorder, neuroendocrine neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, skin disorder, skin neoplasmActive, not recruitingPhase 1 / Phase 22026-02-09NCT04478279

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Sapience Therapeutics3

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Columbia UniversityNew YorkUnited States154
Duke University School of MedicineDurhamUnited States1
Edinburgh Cancer CentreEdinburghUnited Kingdom1
Northwestern Medicine Cancer CentersWarrenvilleUnited States1
Sarah Cannon Research InstituteNashvilleUnited States119
Sarah Cannon Research InstituteDenverUnited States16
Sarah Cannon Research Institute UKLondonUnited Kingdom26
START MidwestGrand RapidsUnited States4
The Beaston West of Scotland Cancer CentreGlasgowUnited Kingdom1
University of California, San FranciscoSan FranciscoUnited States294
University of LeedsLeedsUnited Kingdom1